Back
Edge
StocktwitsEarnings
Official STOCKTWITS Representative
symbol logo$KNSA Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $0.33 up 37.50% YoY • Reported revenue of $243.6M up 55.36% YoY • Kiniksa Pharmaceuticals expects 2026 ARCALYST net product revenue to be between $980 million and $995 million, raised from prior guidance of between $930 million and $945 million for the fiscal year.
2

Price since post

Full Details

Advertisement|Remove ads.